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E-mail: emlhope@iu.eduDendritic cells play a key role in activation of the immune sys-
tem as potent antigen-presenting cells. This pivotal position,
along with the ability to generate dendritic cells from mono-
cytes and ready uptake of antigen, makes them an intriguing
vehicle for immunotherapy for a variety of indications. Since
the first reported trial using dendritic cells in 1995, they have
been used in trials all over the world for a plethora of indica-
tions. Monocyte-derived dendritic cells are generated from
whole blood or apheresis products by culturing enriched
monocytes in the presence of interleukin (IL)-4 and granulo-
cyte-macrophage colony-stimulating factor (GM-CSF). A vari-
ety of methods can be used for enrichment of monocytes for
generation of clinical-grade dendritic cells and are summarized
herein.
In the 2018 Annual Regenerative Medicine Data Report, the Alliance
for Regenerative Medicine reported that 1,028 clinical trials utilizing
specific regenerative medicine or advanced therapeutic technologies
were underway worldwide. Of those trials, 263 were classified as
cellular therapy products, and another 362 were categorized as
gene-modified cellular therapy products.1 While chimeric antigen
receptor (CAR) T cell therapies and adeno-associated virus (AAV)
vector therapies have thrust immunotherapy into the spotlight of
popular media, it is important to note that the first US Food and
Drug Administration (FDA)-approved cellular therapy was a den-
dritic cell (DC) vaccine, sipuleucel-T, or Provenge. This vaccine
was approved by the FDA in 2010 and was marketed by Dendreon.2,3
The first article describing vaccination with a DC vaccine was pub-
lished in 1995, and while no major therapeutic response was noted,
peptide-specific T cells were induced at the site of immunization
and at distant sites.4 By 2003, more than 1,000 patients had received
experimental DC vaccines for various cancer indications.5 More than
16 years later, the website ClinicalTrials.gov had 120 trials listed
world-wide using DCs as a biologic drug (as of August 2019). Search
criteria included “dendritic cell” with the following filters applied:
active; recruiting, not active; and interventional.6 Data gathered
from this search was further filtered to remove trials that did not
include DCs as a biologic drug. Most trials include some combination
of treatment modalities, from hematopoietic stem cell (HSC) trans-
plant, to monoclonal antibodies (checkpoint inhibitors), to chemo-
therapy, to CAR T cells. Figure 1 shows that the vast majority of these
trials are using DCs as a treatment for cancers; however, a few trialsMolecular Therapy: Methods &
This is an open access article under the CC BY-NC-are looking at DCs for treatment of autoimmune disorders, such as
multiple sclerosis or Crohn’s disease, or for treatment of chronic viral
infection, specifically HIV.
DCs are professional antigen-presenting cells. These cells bridge the
gap between innate and adaptive immunity and are able to ingest pro-
teins and present antigens in complex with both major histocompat-
ibility complex (MHC) class I and MHC class II molecules. As such,
they play a key role in regulation of the immune response through
both activation and tolerance.7–9 In the absence of danger signals,
immature DCs are capable of inducing peripheral tolerance to self-
antigens; however, in the presence of danger signals recognized by
pattern recognition receptors, DCs undergo maturation. Mature
DCs migrate to the lymph nodes and have increased expression of
co-stimulatory molecules, such as CD40, CD80, and CD86, and
MHC-peptide complexes on their surface. The additional secretion
of inflammatory cytokines allows mature DCs to fully activate
T cells with production of all three signals by the same cell: signal 1
(antigen presented in the context of MHC), signal 2 (co-stimulation
through upregulation of CD86 and others), and signal 3 (pro-inflam-
matory cytokine secretion).7,10,11
The breadth of indications using DCs as a treatment modality reflects
their important role in eliciting immunity. Various methods for
generating clinical DCs have been developed since their discovery
and characterization as a morphologically unique cell type with a ca-
pacity to activate naive lymphocytes.12–14 While DCs may be isolated
from the blood or generated from hematopoietic progenitor cells,15
the most common method is generation from monocytes using a
combination of granulocyte-macrophage colony-stimulation factor
(GM-CSF) and interleukin (IL)-4.15–18 The focus of this review is
on the methods for monocyte enrichment used to generate these
monocyte-derived DCs.Generation of DCs from Human Monocytes
Generation of monocyte-derived DCs (MoDCs) for immunotherapy
begins with an apheresis collection of peripheral blood mononuclearClinical Development Vol. 16 March 2020 ª 2020 The Authors. 155
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Categories of Current DC Trials Where the
Drug Includes a DC as a Biologic Component of
Treatment
A total of 120 trials met the criteria. Most of them (n = 113)
were for malignancies, further defined as non-hematologi-
cal malignancies (n = 95), and hematological malignancies
(n = 18). Trials for non-malignant indications include auto-
immune disorders (n = 5) and chronic viral infections (n = 2).
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variety of methods, including both open and closed manipulations,
then cultured for approximately 6 days in the presence of IL-4 and
GM-CSF to generate immature DCs. Culturing of the cells can be
done in either flasks or bags and has recently been discussed else-
where.19 Additionally, Corning Life Sciences recently launched a
novel closed, automated perfusion cell culture system, MicroDEN,
developed by Flaskworks.20 Immature DCs generated in the Micro-
DEN system are phenotypically and functionally similar to plate-
generated immature DCs, while manual steps and risk of contamina-
tion are vastly reduced.21 Shorter culture times, as little as 18–24 h,
have been used to generate immature DCs, with an additional 24-h
incubation to induce maturation of DCs.22,23 Cultured DCs are
exposed to the protein or antigen of choice through a variety of
methods, including transfection, transduction using a variety of
viral vectors, or simple addition of tumor lysate or peptides to the
culture medium (peptide pulsing), to fusion of DCs with tumor
cells through co-culture with the addition of polyethylene glycol.24
Immature or mature DCs are harvested and cryopreserved or
administered as a fresh product. Samples of each product are removed
for quality control testing and sterility testing prior to patient
administration.
Open System Methods for Enrichment
Peripheral blood monocytes must be enriched prior to culturing to
deplete contaminating lymphocytes, red blood cells, and platelets.
Monocyte enrichment from peripheral blood mononuclear cells
(PBMCs) by plastic adherence with or without prior density purifica-
tion is one of the classic procedures used in research laboratories for
cell enrichment.25 Ficoll density purification is particularly important
when a high amount of granulocytes and RBCs are present in the
starting material. The tube Ficoll method is commonly used for small
scale applications, however, this is not easily adapted to large scale
processes.26 Large-scale Ficoll gradient methods have been developed
for use in clinical trial, providing good recoveries and a closed sys-
tem.27,28 Apheresis products contain fewer red blood cells (RBCs)
and granulocytes than peripheral blood; however, performing a den-
sity purification on these products can result in higher purity DCs.156 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020A representative description of monocyte enrich-
ment using plastic adherence is to seed 10–
15  106 PBMCs per flask into 25-cm2 cell cul-
ture flasks, and incubate at 5% CO2 and 37C
for approximately 2 h in 5 mL of media to allow
to adherence of the monocytes. At the end of theincubation period, the non-adherent cells are removed, and the
adherent cells are carefully washed twice with media or buffered sa-
line to remove remaining non-adherent or loosely adherent cells.29
Lymphocyte contamination in the first hour after adherence may
be high, as much as 40%–50% after two washes and 30% even after
five washings.30 An expected purity using similar methods at a larger
scale is >67.3% with viability of >99%.31 The relative low cost of sup-
plies, common access to required equipment, and adaptability to
small volumes of starting PBMC material ensures that the process
will continue to be used in research and development work. However,
this monocyte adherence enrichment process is an open manual-
based protocol. The risk of contamination to cell cultures when using
an open multi-flask process, the technical skill required to ensure
adequate removal of non-adherent cells while not inadvertently
removing adherent cells, and time requirement of 4–8 h of initial pro-
cessing indicate that this process is not ideal for large-scale produc-
tion for clinical trials or current Good Manufacturing Practices
(cGMP). Additionally, plastic adherence has been suggested to acti-
vate the monocytes, which may negatively impact DC development.32
A second open method for monocyte enrichment is elutriation using
the counterflow centrifugal elutriation (CCE) cell separating tech-
nique. This method enables cells to be separated based on size. The
key concept is that the larger cells will stay within the flowing buffer
solution while smaller cells will be flushed though the tubing with the
buffer solution. Since cell size is correlated with cell cycle stages, this
method can also be used to separate cells at different stages of the cell
cycle. The sedimentation property differs within the buffer solution.
The cells will have sedimentation properties that differ in the various
cell cycle stages. The basic principle of differentiating the cells using
CCE is the balance between centrifugal force and the counterflow
drag force. When cells enter the elutriation chamber they are all at
the outer edge of the chamber due to centrifugal force. Then, when
the flow rate of the buffer solution is increased the solution pushes
the cells inward toward the middle of the CCE chamber due to the
unique design of the chamber. This is called the counterflow drag
force by the manufacturer. As the flow rate of the buffer solution in-
creases, the counterflow drag force begins to out-compete the
www.moleculartherapy.org
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by the net force and leave the chamber first. In contrast, the larger
cells will stay within the elutriation chamber. Cells that escape from
the elutriation chamber can be collected in the exit of the system,
which consists of a series of collection bags with clamps to direct
flow, allowing segregation of different cell fractions.33
In early studies, the average yield per leukapheresis procedure was
1.5  109 cells, with a purity of 91% using the 40-mL separation
chamber. The recovery of lymphocytes and monocytes was 82% ±
7% and 78% ± 8%, respectively. In vitro analysis of the viability and
function of the purified monocytes shows that neither morphological
integrity nor physiological activity was compromised.34 During the
CCE cell separation technique, the cells are suspended in a buffer so-
lution and enter a centrifuge. The whole process does not involve any
chemical additives to the cells to lyse the cell membrane. Additionally,
there are no physical additives such as the attachment of antibody or
activation of the cells that might impact subsequent functionality of
the cells. The cells effectively remain unchanged before, during, and
after the separation. Therefore, the enriched cells are available for
further experiments, cell culture, or additional separation and enrich-
ment by other techniques.
Because the CCE process relies on centrifugal force and the counter-
flow drag force to collect the cells in fractions as they pass through the
centrifuge, the speed of separation is rapid, and up to 20  109
PBMCs can be elutriated within 1 h.22,35 Alternatively, unlike plastic
adherence, the CCE cell separation technique requires specific and
expensive equipment to allow for processing. The Beckman J-5.0
rotor (Beckman Coulter, Fullerton, CA), which is an open system,
is the current standard.36 There are multiple small parts that are sub-
ject to wear and cracking during handling, so back-up parts must be
available for use. Additionally, although the process is quick, the
setup, decontamination, and subsequent reassembly of the chamber
add at least 4 h to processing. The processing technique can be chal-
lenging to master and can require at least two trained operators to
ensure effective and efficient processing. The elutriation process
also requires a substantial volume of starting material such as a leuka-
pheresis collection for adequate separation. Lastly, as the system re-
mains open and supplies are not single use, the risk of contamination
of a product or between products is high. Validation of equipment
sterilization is required to help control the risk of cross-contamina-
tion. This limits the process usefulness in large-scale production for
clinical trials or cGMP manufacturing.
Closed-System Methods of Enrichment
CCE provides a more pure monocyte preparation than does standard
plastic adherence; however, the open aspect of the system, as well as
the required sterilization of the chamber and tubing, drastically in-
creases the risk of product contamination. To address this, Terumo
BCT (Lakewood, CO, USA) offers a closed system called the Elutra.
This instrument allows monocyte enrichment directly from leuka-
pheresis products using counterflow elutriation. The Elutra incorpo-
rates single-use, functionally sealed disposable sets that contain a 40-MolecularmL elutriation chamber. The equipment can be programed to
increase enrichment for different cell types in each fraction and
also offers a high degree of flexibility with the ability to performmulti-
step separations. Similar to CCE, the Elutra passes fluid through the
cell layer established by centrifugal force. Varying the flow of fluid al-
lows collection of particles based primarily on size, from smallest to
largest, and based on density, from lower to higher. After priming
the Elutra, the leukapheresis product is loaded into the elutriation
chamber using the cell inlet pump. The centrifuge speed is set at
2,400 rpm and held constant. The flow of elutriation media is pro-
gramed to increase slowly in a stepwise fashion to enhance the elutri-
ation of the specific cell fractions into the pre-attached collection bags.
The cell inlet pump speed found to be most advantageous for mono-
cyte enrichment is at a pump flow rate of 37mL/min andmedia pump
speed of 37–97.5–103.4–103.9 mL/min, and approximately 975 mL of
elutriation media per fraction. The centrifuge is stopped and the cells
are pumped at 103.9 mL/min into the final collection bag, or “rotor
off” from the elutriation chamber. The total processing time is
approximately 60–90 minutes.37 The mean monocyte recovery using
an Elutra has be found as high as 94.3%–98.53%.37,38 The average pu-
rity was 73% ± 9% to 82.95% ± 6.01%.37,39
One of the biggest advantages of the Elutra process is the closed, sin-
gle-use disposable system that allows for fast isolation of monocytes
in large quantities within a closed system, decreasing the risk of
contamination and increasing turn-over time for next patient prepa-
ration. Similar to CCE, the cells are also untouched by chemical or
physical additives. In contrast to CCE, the training time and skill level
for operators is consistent with general laboratory techniques. No
advanced training or multiple staff operation is required. The process
is readily adaptable to large-scale production for clinical trials or
cGMP manufacturing. One drawback to sustainable research labora-
tory processing using Elutra for monocyte enrichment directly is the
cost of the sole source supplies and maintenance support. Addition-
ally, the volume of starting material for adequate separation is tar-
geted at a full apheresis product and not smaller peripheral blood
collections.
A second closed system for monocyte enrichment is CD14+ cell se-
lection on the CliniMACS cell selection system (Miltenyi Biotec,
Auburn, CA, USA). Similar to the Elutra, operation of the
CliniMACS does not require advanced training for personnel. The
CliniMACS system allows users to perform large-scale magnetic
enrichment of target cells, or depletion of unwanted cells, in a closed
and sterile environment. The system comprises the CliniMACS Plus
instrument, CliniMACS tubing sets, CliniMACS reagent, and Clin-
iMACS PBS/EDTA buffer. The tubing sets are single use and have
the separation column integrated within the tubing set to maintain a
closed system. They have been designed to process a specific
amount of total cells in a closed and sterile fluid path.40 Installation
of the tubing set is completed by following the image on the
CliniMACS instrument and by following the on-screen instructions,
making it user-friendly.Therapy: Methods & Clinical Development Vol. 16 March 2020 157
Table 1. Monocyte Enrichment Method Comparison
Monocytes Immature DCs Mature DCs
Publication Cell Source Method Purity (%) Recovery (%) Purity (%) Recovery (%) Purity (%) Recovery (%) Maturation Method
Eyrich et al.46
healthy donors,
high-grade glioma
patients
CD14 selection 94 ± 6.1 89 ± 23 N/A N/A N/A 15.3 ± 5.3
tumor lysate 1,000 U/mL
TNF-a, 2,000 U/mL IL-1bElutra 89 ± 1.5 95 ± 24 N/A N/A N/A 14.5 ± 8
Dohnal et al.16
healthy donors,
cancer patients
adherence n.d n.d. N/A N/A 62 ± 5 6 ± 2
50 ng/mL IFN-g,
1–1,000 ng/mL LPS
elutriation 82 ± 3 87 ± 7 N/A N/A 93 ± 2 16 ± 2
CD14 selection 96 ± 2 59 ± 4 N/A N/A 97 ± 0 4 ± 1
depletiona 61 ± 4 41 ± 3 N/A N/A 42 ± 8 15 ± 3
Felzmann et al.45
healthy donors,
cancer patients
adherence n.d n.d. 72 ± 4 25 ± 5 69 ± 6 12 ± 3
50 ng/mL IFN-g,
200 U/mL LPS
CD14 selection 94 ± 4 40 ± 9 97 ± 1 8 ± 3 97 ± 1 4 ± 2
depletiona 61 ± 5 56 ± 7 42 ± 10 21 ± 6 31 ± 8 16 ± 6
Pullarkat et al.47 melanoma patients
adherence n.d n.d. N/A N/A 63 ± 14 2.7 ± 0.96 10 mg/mL gp100,
1 mg/mL LPSdepletiona 52 ± 11 40 ± 9 N/A N/A 72 ± 11 4.84 ± 2.65
N/A, not available (results were not reported); n.d., not done (no data available because adherent cells would have to be disrupted to determine purity or recovery).
aDepletion performed on the Isolex 300i magnetic cell selector (Nexell, Irvine, CA, USA).
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ride (LPS) and LPS-binding protein (LBP) complex.41 It is strongly
expressed on most human monocytes and macrophages. Purification
of monocytes on the CliniMACS system is achieved using anti-CD14
monoclonal antibodies conjugated to superparamagnetic iron
dextran particles.42 The apheresis product is magnetically labeled
with CD14 reagent. The CD14 molecule does not have a cytoplasmic
domain and acts as a co-receptor with Toll-like receptor 4 (TLR4).
Due to the lack of a cytoplasmic domain, binding of the antibody
to CD14 should not trigger activation of monocytes; however, in
recent years, CD14 was found to activate NFAT (nuclear factor of
activated T cells) independent of TLR4.43 Given these findings,
enrichment of monocytes through binding of CD14 may have the po-
tential to activate the cells. The bag containing the labeled cell suspen-
sion is connected to the buffer-primed tubing set and loaded onto the
CliniMACS instrument while the column is exposed to the magnetic
field. The magnetically bound CD14+ cells are retained within the col-
umn while the CD14 cells are washed off the column and are segre-
gated into a waste bag. After extensive washing, the magnetic field is
turned off and the CD14+ cells are pumped through the closed tubing
into a positive fraction bag.44 Initial descriptions of CD14 positive
selection using magnetic beads resulted in high purity of approxi-
mately 96%–97%, but a variable, yet low yield, ranging from 5% to
60% in two studies.16,45 Recent reports show purity of 94% ± 6.1%,
with a recovery of 89% ± 23%.46
Conversely, depletion of non-monocytes with a cocktail of antibodies
can be used to generate a monocyte population that is not directly
attached to magnetic particles. Depletion is achieved by indirectly
labeling non-monocytes, such as T cells, natural killer (NK) cells,
B cells, DCs, and basophils, with biotin-conjugated antibodies and
then binding the biotin-labeled cells with anti-biotin conjugated to
superparamagnetic iron dextran particles. This method is not widely158 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchused for large-scale generation of DC products. The initial large-scale
depletions were performed on the Isolex 300i and removed T cells and
B cells using anti-CD2 and anti-CD19. This method had statistically
significant lower purity of starting monocytes, slightly more than
60%, compared to selection, with typical purities around 95%. Two
out of three studies had a purity below 50%, which is even lower
than DCs manufactured using plastic adherence.16,45 One study was
able to generate mature DCs with a median purity of 72%; however,
in this study, cells were matured with peptide (gp100) and LPS, not
LPS and interferon (IFN)-g.47
Comparisons of Monocyte Enrichment Methods
Direct comparison of monocyte enrichment methods are summa-
rized in Table 1. Plastic adherence is the only technique described
here that can be performed using standard laboratory equipment
and is not limited by the amount of starting material; however, it pro-
vides a lower purity final product, as well as low recovery based on the
total starting monocytes.16,45,47 Larger volumes of starting material
increase the processing time as well as the risk of contamination.
CCE requires specialized equipment that is not single use; however,
it provides excellent recovery and purity of monocytes, which trans-
lates into some of the highest purity and recovery of final products.16
While enrichment of monocytes is fast, decontamination of the
equipment takes approximately 4 h. Other than plastic adherence,
all other methods for monocyte enrichment have the added benefit
of easily moving enriched cells into a functionally closed culture sys-
tem, by collecting the monocytes into bags, limiting the risk of
contamination during the culture period. Closed-system methods,
such as the Elutra and CD14 selection with the CliniMACS, provide
high-purity products but lower recoveries.16,45 These methods also
require specialized equipment and sole-source consumables,
increasing the cost of materials. Depletion of CD2 and CD19 cells,
as described on the Isolex 300i, also requires specialized equipment2020
www.moleculartherapy.org
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rities shown with positive selection on the CliniMACS.16,45,47
Functionally, there are minimal differences reported regardless of the
method of monocyte enrichment. One publication, not shown in
Table 1, compared plastic adherence to magnetic-activated cell sort-
ing (MACS) methods and found that DCs generated frommonocytes
enriched using plastic adherence had a higher phagocytic activity
than did MACS-enriched monocytes; however, the mean fluores-
cence intensity of phagocytic cells in the MACS-enriched monocytes
was higher.29 Of the publications reviewed in Table 1, only Eyrich
et al.46 showed a difference in the quality of DCs based on the method
of purification, and only in the mature DCs. Their results showed that
matured DCs generated from CD14 enrichment had statistically sig-
nificant higher expression of DC markers (CD80, CD83, CCR7, PD-
L1) and CD14 compared to matured DCs generated from elutria-
tion.46 Immature DCs did not show this difference, however, and
the publication did not discuss the impact of increased expression.
Discussion
DCs continue to be used in clinical trials as a means to boost the im-
mune response. Monocyte enrichment is a key step to generating
monocyte-derived DCs for downstream applications, and various
methods for enrichment have been discussed. The method for enrich-
ment appears to have little impact on the quality of the resultant DCs.
The decision of which method to use for enrichment should consider
various factors, including quantity and quality of starting material,
purity required, maturation status of the final product, experience
of personnel manufacturing the DCs, equipment currently available,
and phase of the clinical trial.
While the focus of this review is monocyte-derived DCs, it is evident
that other sources of DCs are being explored for clinical translation,
including generation of DCs from CD34+ progenitor cells, and even
DCs from induced pluripotent stem cells.15,48 Regardless of the source
of DCs, manufacturing strategies need to be reproducible and robust,
with the ultimate goal of providing safe, high-quality products.AUTHOR CONTRIBUTIONS
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